Weekly Recap | Elevance Health -8.19%, heavy-volume sell-off

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

Elevance Health finished the week down 8.19% at $394.48, slightly outperforming the S&P 500’s 8.61% drop by about 0.42 percentage points. Trading was heavy, with the weekly range spanning 14.66%. The stock opened Monday at $438.27 and touched $447.42 before rolling over; Wednesday saw it break below $400 on higher volume, Thursday marked the weekly low at $383.17, and Friday stabilised at $394.48. Average daily volume of roughly 2.03m shares ran about 68% above the 60-day median.

Key Events

Managed-care names faced broad pressure this week. On 17 November, a proposed rule to curb fraud surfaced after the close, sending health insurers lower. CMS audit proposals and Medicare-for-All concerns then kept the sector under pressure, with US health insurers falling for three straight days through Friday. Elevance was caught in the sell-off, down nearly 4% intraday on Wednesday and more than 4% on Friday. Still, the stock outperformed peers on several sessions, and talk of a Medicaid margin recovery plan circulated during the week. Director Ramiro G. Peru reported buying $383,860 in common shares on Friday, one of the few company-specific positives in an otherwise regulatory-driven week.

Analyst Ratings

Across 22 covering brokers, 13 rate the stock buy, 3 rate it overweight, and 6 rate it hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target of $482.38 sits roughly 22.3% above spot. Individual targets range from $406 to $523, pointing to a wide spread. Within the managed-care industry of nine names, Elevance ranks third on analyst ratings.

The Week Ahead

On the macro front, 24 November brings FHFA house prices, Case Shiller 20-city home prices, consumer confidence (prior 91.7, estimate 92.5), and the Richmond Fed composite index. Company-specific catalysts are further out: Elevance reports FY2026 results before the open on 27 January 2027, with consensus estimates at EPS of $22.4279 and revenue of $198.8bn.

In Short

The week paired a steep sell-off with an analyst community that still largely rates the stock buy and carries a consensus target above spot, leaving a tension between price action and conviction. Fresh daily fund flows also showed net buying from smaller lots against net selling from large lots, highlighting disagreement within the tape. The key follow-through now is how the regulatory proposals evolve and whether next week’s macro prints shift sentiment in the managed-care group.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.